


## CL2A

<b>Cat. No.:</b>	HY-128945
<b>CAS No.:</b>	2616704-22-2
<b>Molecular Formula:</b>	C <sub>50</sub> H <sub>79</sub> N <sub>9</sub> O <sub>16</sub>
<b>Molecular Weight:</b>	1062.21
<b>Target:</b>	ADC Linker
<b>Pathway:</b>	Antibody-drug Conjugate/ADC Related
<b>Storage:</b>	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 200 mg/mL (188.29 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	0.9414 mL	4.7072 mL	9.4143 mL
5 mM	0.1883 mL	0.9414 mL	1.8829 mL
10 mM	0.0941 mL	0.4707 mL	0.9414 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

CL2A is a cleavable complicated PEG8- and triazole-containing PABC-peptide-mc linker. CL2A is cleavable through pH sensitivity, giving rise to bystander effect, and binds the antibody at a cysteine residue via a disulfide bond. Labetuzumab govitican used this linker<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

Cleavable Linker

### REFERENCES

[1]. Samantha Congreve, et al. Antibody drug conjugates (ADC). Teknisk- naturvetenskaplig fakultet

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA